Per the terms of the agreement, Nanowear will use glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) synchronously alongside Nanowear’s previously FDA-cleared cardiovascular ...
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...
Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025.
7don MSN
In a new study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day ...
Zacks.com on MSN4d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The ...
Medicare Part B should cover several types of CGMs, including the Dexcom G7 or its earlier version, the Dexcom G6. What part of Medicare covers the Dexcom G7? Generally, Medicare Part B covers ...
DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM).
Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback